TFA-01 DEVELOPMENT
Centered on Antcin A, TFA-01 advances through molecule and rights, CMC, safety, canine osteoarthritis evidence, and regulatory and commercialization milestones. It remains investigational and is not approved.
LEAD PROGRAM · TFA-01
TFA is evaluating an Antcin A-centered investigational program as a potential non-steroid option for canine osteoarthritis.
TFA-01 DEVELOPMENT FRAMEWORK
Each block separates the foundation already in place, work underway and the next verifiable milestone. The five dimensions are connected; progress in one reduces a defined risk but does not mean the product is approved.
Published studies support GR/GRα-related signaling for Antcin A in defined models. TFA-01 test-article, batch and indication bridging remains underway.
Next milestoneComplete candidate test-article and batch definition and strengthen program-level pharmacology relevant to canine osteoarthritis.View progress detailsResearch across dozens of strains and content profiles is being connected to controlled cultivation, source selection, purification, analytics and formulation development.
Next milestoneComplete physicochemical validation of the nano-enabled clear aqueous formulation, then advance formal specifications, batch consistency and process scale-up.View progress detailsA 14-day preliminary toxicology study in female rats is complete and a report is available to inform later study design. Target-animal safety, toxicology and residue work continues.
Next milestoneComplete subsequent formal regulatory toxicology reports and establish a program-specific safety range for the purified candidate drug substance and final product.View progress detailsThe Shanghai Pet GCP Clinical Trial Team completed a two-week exploratory observation in 15 dogs. It can inform later protocol design but does not establish efficacy.
Next milestoneComplete a standardized canine osteoarthritis study with a full protocol, prespecified endpoints and a statistical analysis plan.View progress detailsTaiwan veterinary-drug data integration continues while the U.S. CVM path is being planned. Partnership and licensing evaluation will follow the maturity of the evidence.
Next milestoneObtain clear regulatory feedback on study design, process specifications and remaining data gaps, then form an executable submission plan.View progress details01 · Molecule, mechanism & rights
Published studies support GR/GRα-related signaling for Antcin A in defined models. TFA-01 test-article, batch and indication bridging remains underway.
Published foundation / program validation underway
Under a publicly filed cooperation agreement entered into in June 2026, TFA received exclusive worldwide development, commercialization and licensing rights for the Antcin A platform. Legal ownership of the platform assets remains with the platform rights holder identified in that agreement.
SEC 6-KTFA-01 is centered on Antcin A. Published studies provide mechanistic signals from cell, computational and preclinical models, while global platform rights are exercised under the publicly filed cooperation and licensing structure.
Current TFA-01 test articles and batches are being connected to the published research context, with further translational pharmacology relevant to canine osteoarthritis.
Complete candidate test-article and batch definition and build a program-specific pharmacology package for later safety and clinical work.
Available studies do not establish direct biochemical binding between Antcin A and GR, canine or human clinical efficacy, program-specific pharmacokinetic parameters, or drug approval.
02 · CMC CORE ADVANTAGE
For a naturally derived molecule, the challenge is not merely access to the compound; it is the ability to source, identify, purify and repeatedly manufacture it to a defined specification. TFA’s CMC path begins at the source and connects cultivation, candidate selection, analytics, purification, specifications and batch bridging.
TFA’s advantage is not simply access to Antcin A. It is the stepwise control chain connecting strain selection, controlled cultivation, composition analysis, purification and batch traceability.
Source foundation in place / specifications and batch bridging underwayTFA is advancing nano-enablement and clear aqueous formulation work to improve the dispersion and formulation feasibility of lipophilic Antcin A in an aqueous system.
Aqueous solubility, clarity, particle size, uniformity and stability remain to be validated. A final dosage form or submission-ready formulation specification has not been established.
TFA has accumulated research across dozens of strain sources and content profiles. Together with controlled cultivation, process optimization and granted cultivation-technology patents in four jurisdictions, this supports source-candidate selection.
Current work covers Antcin A assay and identity analysis, research-scale purification, batch definition, and feasibility development for a nano-enabled clear aqueous formulation.
Validate aqueous solubility, clarity, particle size and stability; define formal specifications and a COA framework; and advance batch consistency, process scale-up, GMP and regulatory validation.
Formal specifications, COAs, batch consistency, commercial scale-up and GMP validation are not complete. The nano-enabled clear aqueous formulation remains under physicochemical validation and is not a final dosage form.
The public site states the research scale and development direction. Strain IDs, individual content results, cultivation parameters, selection criteria and purification conditions remain in confidential DD materials.
03 · Safety & toxicology
A 14-day preliminary toxicology study in female rats is complete and a report is available to inform later study design. Target-animal safety, toxicology and residue work continues.
14-day preliminary toxicology report available / formal work underway
The Company completed a 14-day preliminary TF-15 toxicology study in 24 female rats and holds the report, which can inform dose selection and design for later formal studies.
Target-animal safety, toxicology and residue work continues and must be bridged to current TFA-01 test articles and batches.
Complete subsequent formal regulatory toxicology reports and establish a program-specific safety range for the purified candidate drug substance and final product.
The preliminary screen was not GLP regulatory toxicology or a long-term safety study. It does not establish canine safety, long-term safety, or the safety of purified Antcin A or a final product.
04 · Canine OA clinical development
The Shanghai Pet GCP Clinical Trial Team completed a two-week exploratory observation in 15 dogs. It can inform later protocol design but does not establish efficacy.
Exploratory observation completed / formal study to be established
The 15-dog exploratory observation provides early study experience that can inform later formal trial design.
Available observations are being used to plan clearer eligibility criteria, endpoints, assessment timing and statistical methods.
Complete a standardized canine osteoarthritis study with a full protocol, prespecified endpoints and a statistical analysis plan.
The exploratory observation lacks the full protocol, prespecified endpoints and statistical analysis needed for confirmatory conclusions. It does not establish clinical efficacy or safety, equivalence to dexamethasone, or superiority over dexamethasone.
Two-week exploratory observation
Exploratory comparator
Two-week early observation
This limited exploratory observation does not include the complete protocol, prespecified endpoints and statistical package needed for confirmation; it cannot establish efficacy, long-term safety, clinical equivalence or comparative superiority.
05 · Regulatory & commercialization
Taiwan veterinary-drug data integration continues while the U.S. CVM path is being planned. Partnership and licensing evaluation will follow the maturity of the evidence.
Taiwan advancing / U.S. CVM planning
Integrating CMC, safety and canine osteoarthritis work around the current pathway.
Planning the data-gap review, advisory support and agency communication strategy.
Evaluating regional licensing, co-development and manufacturing as evidence matures.
TFA has established a cross-market rights and cooperation framework and is organizing development data around Taiwan’s veterinary-drug pathway.
CMC, safety and canine osteoarthritis work are being connected into a regulatory evidence path, while U.S. CVM advisory and agency communication are being planned.
Obtain clear regulatory feedback on study design, CMC specifications and remaining data gaps, and convert it into an executable submission plan.
Regulatory acceptance, application acceptance, drug approval, launch timing and commercial outcomes have not been established.
PUBLISHED SCIENCE
Cell, absorption-model and preclinical studies do not establish clinical safety or efficacy.
PLATFORM EXPANSION
The current primary development focus for TFA-01.
One potential future veterinary indication for evaluation.
A future research opportunity subject to scientific and clinical review.
